SCHEMBL6170711

SCHEMBL6170711

C=CCN(Cc1ccc(C(=O)OC(C)(C)C)cc1)C(=O)c1cc(Br)ccc1I

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LSS P48449 5/20 0.40
PYCR1 P32322 1/20 0.35
ALDH1A1 P00352 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
HDAC1 Q13547 3/20 0.32
LMNA P02545 2/20 0.32
KDM4E B2RXH2 2/20 0.32
HDAC3 O15379 1/20 0.32
HDAC2 Q92769 1/20 0.32
NCOR2 Q9Y618 1/20 0.32
GFER P55789 1/20 0.32
GAA P10253 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
HDAC6 Q9UBN7 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6168711 0.74 KMT2A (0.43) HDAC1KDM4EHDAC3HDAC2GAA
SCHEMBL17215529 0.72 CES2 (0.38) ALDH1A1SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL277667 0.66 CA1 (0.53) ALDH1A1SMN1; SMN2CYP2D6CYP2C9CYP2C19
SCHEMBL271075 0.65 GABRA1 (0.44) ALDH1A1KDM4EGAASLC7A5MAPT
SCHEMBL19120562 0.65 GPR119 (0.49) LSSSMN1; SMN2CYP1A2CYP2D6CYP2C19
SCHEMBL9826799 0.65 CYP4A11 (0.45) ALDH1A1L3MBTL1KMT2A
SCHEMBL19900085 0.64 SMN1; SMN2 (0.40) ALDH1A1SMN1; SMN2CYP1A2CYP2D6CYP2C9
SCHEMBL19153323 0.64 HDAC3 (0.52) ALDH1A1HDAC1LMNAHDAC3HDAC2
SCHEMBL7385067 0.63 CA1 (0.50) ALDH1A1HDAC1TDP1HDAC6SLC7A5
SCHEMBL23997350 0.63 PYCR1 (0.54) LSSPYCR1ALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1530472-A1 ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-05-18 EP disclosed
US-20040044000-A1 Isoquinoline derivatives as matrix metalloproteinase inhibitors BUNKER AMY MAE (US) 2004-03-04 US disclosed
WO-2004014379-A1 ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044000-A1 Isoquinoline derivatives as matrix metalloproteinase inhibitors MMP1, MMP13, MMP9 LSS 2404/4885PYCR1 3451/4885ALDH1A1 1297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.